US Pharma MarketingFDA reminds investors about the risks of advisory panels
Two days, two similar briefing documents and two companies with diving share prices. The FDA this week laid out its concerns with clinical data from both Capricor Therapeutics and
Two days, two similar briefing documents and two companies with diving share prices.
The FDA this week laid out its concerns with clinical data from both Capricor Therapeutics and
Source: Endpoints News